Pinned Tweet
You have to be always drunk. That's all there is to it; it's the only way. So as not to feel the horrible burden of time that breaks your back and bends you to the earth, you have to be continually drunk.
But on what? Wine, poetry or virtue, as you wish. But be drunk
Baudelaire
26
7,237
#PeriniPicks no. 9 for #ASH26
This is actually a 2 abstract Pick for the same problem: long term toxicity of steroids.
First, the Sail trial of Adrenal Insufficiency (6.2%) of lymphoma patients treated with steroids. Long term toxicity (~8 months) with a >2.5 fold risk of mortality (although I see some bias here, since these patients needed more therapy).
onlineprogram.hematology.org…
Second, risk of fractures after 1st line R-CHOP in >20.000 Korean patients. Another long term toxicity of steroids we don't pay too much attention.
onlineprogram.hematology.org…
Why is this important?
Because first, we need a non-inferiority trial of One day x 5 day steroid in R-CHOP Backbone...
Second, because with bispecifics moving on first line therapy, there will be an increase in steroid exposure. We should definitely see how this impact in those long term adverse events...
45
#PeriniPicks for #ASH26 Starting Right Now!
And No. 10 is a small ph2 of Lorlatinib, a 3rd generation ALK-inhibitor in R/R ALK+ Malignancies (Mainly lymphomas).
Estimated 18-month PFS and OS rates were 75% and 88%
onlineprogram.hematology.org…
In a very challenging situation, ORR of 100%. Suitable for bridge for Allo.
It's beyond time we move on with trials of Lorlatinib + Chemo in first line therapy, especially in ALK+ LBCL.
Anyone else having trouble seeing the #ASH26 abstracts?
3
4
788
My POV:
What % of IPS 3-7 achieves PET2 neg with BRECADD?
Not keen to give 6 cycles of BRECADD if it is what it takes for 5% PFS difference.
In 10y, secondary neoplasms will take its toll...
BrECADD or nivo-AVD? GHSG and SWOG pooled their patient-level data.
Stage III/IV, 18-60: 3-yr PFS 94.9% vs 90.6%, febrile neutropenia 29% vs 6%, OS similar.
Weighted, not randomized. Gap mostly in IPS 3-7. Accept more toxicity there?
#ASH26 #lymsm #HodgkinLymphoma
onlineprogram.hematology.org…
While impressive, median follow up is short and n is small.
Chemo-based regimens + BTKi remains SoC... for now.
Chemo-free 1L MCL at #ASH26 (investigational):
GATE1 pirto-ven-R, n=50, 34% TP53-altered: CR 96%, 12-mo PFS 96% (mFU 8 mo)
TrAVeRse acala-ven-R, n=108: 22-mo PFS 89%, TP53m 82%
TP53m pts doing well early. Next question: is MRD-neg stop safe? @YucaiWangMD #lymsm #MCL
I wish these biespecifics would be tested in Angioimmunoblastic T-cell lymphomas...
PD(L)1-VEGF bispecifics are already beating PD1 inhibition alone in trials, so what's next?
This trial (BioNTech, DualityBio, BMS) adds a new B7-H3 ADC to a PDL1-VEGF bispecific, with potential synergy:
1) VEGF blockade: normalizes tumor vasculature, improves ADC delivery and T cell infiltration.
2) B7-H3 ADC: kills cancer cells, triggers immunogenic inflammation.
3) PDL1 blockade: releases immune suppression, allows T cells to exploit immune response induced by ADC.
Confirmed ORR up to 71% -- in immune-cold platinum-resistant ovarian cancer.
The broader, ongoing phase 2 includes colorectal cancer, pancreatic cancer and other tumor types.
Guilherme Perini, MD retweeted
Impact of healthcare setting on survival in adults with acute lymphoblastic leukemia in Latin America: insights from a large multinational cohort - The Lancet Regional Health – Americas thelancet.com/journals/lanam… 🇦🇷🇧🇷🇨🇱
Guilherme Perini, MD retweeted
On the 3rd anniversary of October 7, it’s important to remember the full hideous horror of what Hamas did that day to the Israeli people - and to condemn it, unequivocally.
Those who still refuse to condemn it are complicit in supporting terrorism.
Guilherme Perini, MD retweeted
Review: N-AVD or BrECADD for Advanced-Stage Classical Hodgkin Lymphoma: Choosing the Right Treatment for the Right Patient
clinical-lymphoma-myeloma-le…
Yes, but lets not forget that the RR scenario is in constant improvement.
Might take years for an OS benefit.
I think if the difference in PFS remains in longer follow ups, we have a winner!
Replying to @tobyeyre82
HR 0.49 certainly has my attention. But before we "CHOP" R-CHOP from the frontline, I want to know we’re actually curing more patients.
Frontline DLBCL is curative. My bar for adding a bispecific to R-CHOP is higher than improving PFS alone. Show me the curves. Show me the toxicity. Show me the OS.
PFS gets my attention. OS changes my practice.
Ok, looks like Epco-R-CHOP is ready for primetime.
HR 0.49 is impressive, and will probably be the new SoC.
What we eagerly wait:
1. Toxicity data
2. How Glofi-Pola-R-CHP will perform in the ph3 trial
3. Molecular data
Exciting times ahead!
Guilherme Perini, MD retweeted
This should be pushed far and wide. Watched in every college class in the U.S. Thank you @billmaher The moral confusion is gross. "It is not a genocide, it is a counterattack in a war...Gaza equals genocide is a lie, an easily provable lie (as I have argued from first hand observations in Gaza). The fact that so many democrats go along with it is to me the party's worse moment since they undid reconstruction after the civil war...words have meaning...genocide, kill or try to kill an entire people, you can't just change the definition of genocide to mean counterattack in a war where people including civilians die, that's every war..."
If Anthracycline is Key, why should we celebrate a regimen that has lower dosis of Doxo compared to the ABVD backbone?
Let the war begins...
New paper alert 👀 thank you to @Haematologica for publishing our analysis of ~30,000 UK classic Hodgkin lymphoma patients, with a focus on the ever-interesting older population. NB: anthracycline is key! haematologica.org/article/vi… @DavidJCutter @graham74GC
12
3,207
Para surpresa de zero pessoas.
Os caras sao lendas vivas.
Crítica: Roupa Nova e Guilherme Arantes fazem um dos melhores shows do Rock in Rio 2026
oglobo.globo.com/cultura/mus…
1
5
643
This might be the most non-sense idea I have ever read.
Whats next?
Abandon talking to patients?
A call to abandon performative physical examinations. Join me?
Physical Examination for Asymptomatic Adults | New England Journal of Medicine nejm.org/doi/full/10.1056/NE…
1
9
2,487
We only transplant what we dont know how to treat.
🤔🤔🤔🤔🤔
Ibrutinib versus allogeneic haematopoietic stem cell transplant in relapsed/refractory del(17p) chronic lymphocytic leukaemia/small lymphocytic lymphoma onlinelibrary.wiley.com/doi/… #CLL #leusm




















